• Kontakt
• So finden Sie uns
• Klinikumseinrichtungen
• Presse

Publikationen

Behe M., Alt K., Deininger F., Bühler P., Wetterauer U., Weber W. A., Elsässer-Beile U., Wolf P.
In Vivo Testing of 177Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer.
In Vivo. Jan.-Feb. 25(1):55-9 (2011).

Wolf P., Alt K., Wetterauer D., Bühler P., Gierschner D., Katzenwadel A., Wetterauer U., Elsässer-Beile U.
Preclinical evaluation of a recombinant anti-PSMA single-chain immunotoxin against prostate cancer.
J Immunother, 33:262–271 (2010).

Bühler P., Wetterauer D., Gierschner D., Wetterauer U., Elsässer-Beile U. and Wolf P.
Influence of Structural Variations on Biological Activity of anti-PSMA scFv and Immunotoxins Targeting Prostate Cancer.
Anticancer Res, Apr. 30:3373-3379 (2010).

Fortmüller K., Alt K., Wolf P., Gierschner D., Baum V., Freudenberg N., Elsässer-Beile U.,
Bühler P.
Effective Targeting of Prostate Cancer by Lymphocytes Redirected by a PSMAxCD3 Bispecific Single-Chain Diabody.
Prostate, 2010 Oct 13. [Epub ahead of print].

Wolf P., Freudenberg N., Bühler P., Alt K., Schultze-Seemann W., Wetterauer U.,
Elsässer-Beile U.
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Prostate, Apr 1;70(5):562-9 (2010).

Alt K., Wiehr S., Ehrlichmann W., Reischl G., Wolf P., Pichler B. J., Elsässer-Beile U., Bühler P.
High-resolution Animal PET Imaging of Prostate Cancer Xenografts With Three Different 64Cu-Labeled Antibodies Against Native Cell adherent PSMA.
Prostate, Sep15; 70(13):1413-1421 (2010).

Bühler P., Wolf P., Katzenwadel A., Schultze-Seemann W., Wetterauer U., Freudenberg N., Elsässer-Beile U.
Primary prostate cancer cultures are models for androgen-independent transit amplifying cells.
Oncol Rep, Feb;23(2):465-70 (2010).

Bühler P., Fischer T., Wolf P., Gierschner D., Schultze-Seemann W., Wetterauer U. and Elsässer-Beile U.
Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
Urol Int , 84:203–211 (2010).

Wolf P., Elsässer-Beile U.
Pseudomonas Exotoxin A: from virulence factor to anti-cancer agent.
Int J Med Microbiol, 299(3): 161-176 (2009).

Elsässer-Beile U., Bühler P., Wolf P.
Targeted Therapies for Prostate Cancer against the Prostate Specific Membrane Antigen.
Current Drug Targets, Feb;10(2):118-25 (2009).

Wolf P., Elsässer-Beile U.
Pseudomonas Exotoxin A based immunotoxins for targeted cancer therapy. In Emerging Cancer Therapies, Microbial Approaches and Biotechnological Tools.
John Wiley and Sons, Inc. 2010, ISBN: 978-0-470-44467-2.

Bühler P., Molnar E., Dopfer E. P., Wolf P., Gierschner D., Wetterauer U., Schamel W. W. A., Elsässer-Beile U.
Target-dependent T Cell Activation by Co-Ligation with a PSMAxCD3 Diabody Induces Lysis of Prostate Cancer Cells.
J of Immunother, 32: 565-573 (2009).

Liu J., Kopečková P., Bühler P., Wolf P., Pan H., Bauer H., Elsässer-Beile U., Kopeček J.
Biorecognition and Subcellular Trafficking of HPMA Copolymer – Anti PSMA Antibody Conjugates by Prostate Cancer Cells.
Mol Pharm, Jun-Jul;6(3):959-70 (2009).

Elsässer-Beile U., Reischl G., Wiehr S., Bühler P., Wolf P., Alt K., Ca F., Shively J., Machulla H.-J., Pichler B. J.
PET Imaging of Prostate Cancer Xenografts with a highly specific antibody against the prostate specific membrane antigen.
J Nucl Med, 50(4): 606-611 (2009).

Bühler P., Wolf P., Elsässer-Beile U.
Targeting the prostate specific membrane antigen for prostate cancer therapy.
Immunotherapy, 1(3): 471-481 (2009).

Wolf, P., Alt, K., Bühler, P., Katzenwadel, A., Wetterauer, U., Tacke, M., Elsässer-Beile, U.
Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Prostate 68(2), 129-138 (2008).

Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W.W.A., Elsässer-Beile, U.
A bispecific diabody directed against prostate specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Cancer Immunol. Immunother, 57(1), 43-52 (2008).

Bühler, P., Wolf, P., Reischl, G., Pichler, B., Shively, J., Alt, K., Wetterauer, U., Elsässer-Beile, U.
PET Imaging of prostate cancer with a highly specific anti-PSMA antibody.
Tumor Biol 28 (Suppl 1) p. 90 (2007).

Wolf, P., Alt, K., Bühler, P., Wetterauer, U., Elsässer-Beile, U.
Selective Suppression of human prostate tumor growth in mice by a recombinant anti-PSMA immunotoxin.
Tumor Biol 28 (Suppl 1) p. 68 (2007).

Elsässer-Beile, U., Wolf, P., Gierschner, D., Bühler, P., Schultze-Seemann, W., Wetterauer, U.
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
The Prostate 66 (13), 1359-1370,( 2006).

Wolf, P., Gierschner, D., Bühler, P., Wetterauer, U., Elsässer-Beile, U.
A recombinant PSMA-specific single-chain immunotoxin (A5-PE40) has potent and selective toxicity against prostate cancer cells.
Cancer Immunol Immunother, 55 (11), 1367-1373 (2006).

Bühler, P., Leiber, C., Lucht, M, Wolf P., Wetterauer, U. , Elsässer-Beile, U.
Intravesical mistletoe extract for adjuvant treatment of superficial urinary bladder cancer.
PharmacologyOnLine, 3, 442-448 (2006).

Elsässer-Beile, U., Rostock, M., Bühler, P., Wetterauer, U., Schumacher, M., Bartsch, H.
Immunological effects of Echinacea purpurea extract in patients with breast cancer.
PharmacologyOnLine, 3, 474-481(2006).

Elsässer-Beile, U., Leiber, C., Bühler, P., Mengs, U., Wetterauer, U.
Adjuvant intravesical treatment of superficial urinary bladder cancer with Mistletoe extract.
Tumor Biol 27 (Suppl 1), p. 25 (2006).

Bühler, P., Elsässer, U., Freudenberg, N., Wetterauer, U.
Primary tumor cultures as model for androgen depletion of prostate cancer.
Tumor Biol 27 (Suppl 1) p. 56 (2006).

Bühler, P., Freudenberg, N., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Elsässer-Beile, U.
Hormonal ablation in primary prostate cancer cultures – Effects on cell growth and gene expression.
Tumor Biol 27(Suppl 2) p. 36 (2006).

Wolf, P., Bühler, P., Gierschner, D., Wetterauer, U., Elsässer-Beile, U.
A recombinant PSMA-specific single-chain immunotoxin as therapeutical option for prostate cancer.
Tumor Biol 27(Suppl 2) p. 97 (2006).

Elsässer-Beile, U., Bühler, P., Wolf, P., Katzenwadel, A., Wetterauer, U.
T-Cell mediated lysis of prostate cancer cells with a single-chain PSMA/CD3 bispecific antibody.
Tumor Biol 27(Suppl 2) p. 36 (2006).

Elsässer-Beile, U., Leiber, C., Wolf, P., Lucht, M., Mengs, U., Wetterauer, U.
Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
J. Urol 174, 76-79, (2005).

Elsässer-Beile, U., Leiber, C., Wetterauer, U., Bühler, P., Wolf, P., Lucht, M., Mengs, U.
Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
Anticancer Res. 25, 4733-4736, (2005).

Preise